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Abstract
Aim: To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarc-
tion [MI] and nonfatal stroke) and hospitalization for heart failure (HF) in the
SUSTAIN (subcutaneous semaglutide) and PIONEER (oral semaglutide) trials across
subgroups of varying CV risk.
Methods: Post hoc analyses of individual patient-level data combined from SUSTAIN
6 and PIONEER 6 were performed to assess MACE and HF. MACE were analysed in
subjects with and without: established CV disease and/or chronic kidney disease;
prior MI or stroke; and prior HF. MACE in the SUSTAIN and PIONEER glycaemic effi-
cacy trials were also assessed.
Results: In SUSTAIN 6 and PIONEER 6 combined, the hazard ratio (HR) for effect of
semaglutide versus placebo on overall MACE was 0.76 (95% CI 0.62, 0.92), which
was mainly driven by the effect on nonfatal stroke (HR 0.65 [95% CI 0.43, 0.97]). The
HR for hospitalization for HF was 1.03 (95% CI 0.75, 1.40). The HRs for MACE were
<1.0 in all subgroups, except for those with prior HF (HR 1.06 [95% CI 0.72, 1.57]);
P-values for interaction of subgroup on treatment effect were >0.05, except for HF
(0.046). In the combined glycaemic efficacy trials, the HR for effect of semaglutide
versus comparators on MACE was 0.85 (95% CI 0.55, 1.33).
Conclusions: In SUSTAIN and PIONEER combined, glucagon-like peptide-1 analogue
semaglutide showed consistent effects on MACE versus comparators across varying
CV risk. No effect of semaglutide on MACE was observed in subjects with prior HF.
ClinicalTrials.gov: NCT02054897, NCT01930188, NCT01885208, NCT02128932,
NCT02305381, NCT01720446, NCT02906930, NCT02863328, NCT02607865,
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1 | INTRODUCTION
Cardiovascular (CV) disease (CVD) is the leading cause of morbidity
and mortality in patients with type 2 diabetes (T2D).1 CV outcomes
trials (CVOTs) have demonstrated the CV safety of several glucose-
lowering drugs. Moreover, some drugs, such as the glucagon-like
peptide-1 (GLP-1) receptor agonists (GLP-1RAs) liraglutide,2
albiglutide3 and dulaglutide,4 and sodium-glucose co-transporter-2
inhibitors (SGLT-2is) empagliflozin5 and canagliflozin,6 have shown a
reduction in major adverse cardiovascular events (MACE) versus pla-
cebo. SGLT-2is have also been shown to reduce the risk of hospitali-
zation for heart failure (HF),5-7 an endpoint for which liraglutide and
dulaglutide demonstrated a neutral effect in CVOTs.2,4 The majority
of CVOTs include patients with established CVD. The strength of
these data is now reflected in treatment guidelines, which recommend
a GLP-1RA or an SGLT-2i in those with CVD.8,9
There are several mechanisms through which GLP-1RAs may
mediate their CV effects, including improving cardiac function and
attenuating atherothrombosis,10 with the strongest evidence
supporting an effect on atherosclerosis.11 CV benefits with GLP-1RAs
could, therefore, be expected in those with atherosclerosis without
established CVD, although they may take longer to manifest. Indeed,
there is evidence to support CV benefits of GLP-1RAs in such patients,
including data from a CVOT in which a majority of patients did not
have established CVD.4 As the incidence of MACE in patients without
established CVD is lower than in those with, analyses of large datasets
are required to verify whether CV benefits apply to these patients.
Semaglutide (Novo Nordisk, Denmark) is a long-acting human
GLP-1 analogue, which can be administered once weekly subcutane-
ously (s.c.), or once daily orally when co-formulated with the absorp-
tion enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
(commonly known as ‘SNAC’).12,13 The half-life (~7 days) and clinical
effects of semaglutide are similar irrespective of mode of administra-
tion.14,15 Both formulations lowered HbA1c and body weight versus
comparators across the continuum of care in subjects with T2D in the
SUSTAIN (s.c.)16-22 and PIONEER (oral)23-31 phase 3a clinical trial
programmes.
SUSTAIN 6 and PIONEER 6 were preapproval CVOTs of s.c. and
oral semaglutide, respectively, with similar designs and populations.32,33
Key differences included planned duration and treatment arms.
SUSTAIN 6 was time- and event-driven (≥104 weeks’ exposure and
≥122 primary outcome events),32 whereas PIONEER 6 was solely
event-driven (≥122 primary outcome events).33 SUSTAIN 6 was a four-
armed trial (semaglutide 0.5 mg and 1.0 mg once weekly, and volume-
matched placebo), with the primary analysis performed on pooled
semaglutide and placebo groups,32 whereas PIONEER 6 was a two-
armed trial (oral semaglutide target dose 14 mg once daily and
placebo).33 The primary outcome in both trials was the time to first
occurrence of a three-component MACE (CV death, nonfatal myocar-
dial infarction [MI], or nonfatal stroke).32 There were fewer MACE with
semaglutide versus placebo in both trials: the hazard ratios (HRs) for
SUSTAIN 6 and PIONEER 6 were 0.74 (95% confidence interval
[CI] 0.58, 0.95) and 0.79 (0.57, 1.11), respectively.32,33 In SUSTAIN
6, the results were significant for noninferiority and superiority,
although the latter was not prespecified.32
SUSTAIN 6 and PIONEER 6 aimed to rule out an excess risk of
CV events with semaglutide versus placebo, defined by the US Food
and Drug Administration as having an upper bound of the 95% CI
<1.8 in preapproval trials. Both trials, therefore, enrolled fewer sub-
jects and were shorter in duration (median follow-up: 2.1 years in
SUSTAIN 632 and 1.3 years in PIONEER 633) than CVOTs, with the
aim of showing safety in a postapproval setting or powered to show
superiority.
The aim of this analysis was to assess the effects of semaglutide
(s.c. and oral) versus placebo on MACE and hospitalization for HF in sub-
jects with T2D in a combined population from SUSTAIN 6 and PIONEER
6, and to evaluate the effect across clinically relevant CV risk subgroups.
To support these analyses, MACE in the combined phase 3a glycaemic
efficacy trials were also analysed. Our expectation was that analyses of
all available datasets would enable a more robust assessment of the
effect of semaglutide on MACE in subjects with T2D across the diverse
spectrum of CV risk encountered in clinical practice.
2 | MATERIALS AND METHODS
2.1 | Trial design and participants
The previously reported32,33 trial designs for SUSTAIN 6 and PIONEER
6 are summarized in Table S1. In both, randomization was stratified
based on the same criteria for evidence of CVD at baseline: established
CVD and/or chronic kidney disease (CKD), or CV risk factors only.
Trial designs and endpoints for the SUSTAIN and PIONEER phase
3a glycaemic efficacy trials (SUSTAIN 1–5 and two SUSTAIN JAPAN
trials, and PIONEER 1–5, 7–8 and the two PIONEER Japanese trials
[9 and 10]) are summarized in Tables S2 and S3, and have also been
reported previously.16-31
All studies were approved by Independent Ethics Committees
and Institutional Review Boards at each participating centre and con-
ducted in compliance with the International Conference on
Harmonisation Good Clinical Practice guidelines and the Declaration
of Helsinki. All subjects provided written informed consent before any
trial-related activities. All authors had full access to all study data and
take responsibility for their integrity and analyses.
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2.2 | Outcomes and subgroups
In our post hoc analysis, the incidences of the adjudicated three-
component MACE and its individual components were analysed using
individual patient-level data from the combined population of
SUSTAIN 6 and PIONEER 6. In addition to the fatal MI and stroke
components of MACE, the incidences of fatal plus nonfatal MI and
fatal plus nonfatal stroke events, as well as hospitalization for HF,
were assessed in the combined population.
The incidences of adjudicated MACE in subgroups from the com-
bined population of SUSTAIN 6 and PIONEER 6 were also analysed. Sub-
groups were defined according to the same criteria for evidence of CVD
at screening and CV risk strata in the trials’ inclusion criteria (Table S1). In
two other subgroup analyses, subjects were defined according to occur-
rence of prior MI or stroke, or prior HF (New York Heart Association
[NYHA] Class II–III) as assessed by medical history (yes/no).
The incidences of MACE were also analysed across the combined
population from the phase 3a glycaemic efficacy trials (SUSTAIN 1–5 and
two SUSTAIN JAPAN trials, and PIONEER 1–5, 7–8 and the two PIO-
NEER Japanese trials [9 and 10]). In these trials, MACE were recorded as
adjudicated adverse events (AEs) using the same terms as the CVOTs (MI,
stroke and CV death). The individual components of MACE are not
reported for this population because of the low numbers of events.
2.3 | Statistical analyses
Post hoc analyses of SUSTAIN 6 and PIONEER 6 data combined on a
patient level were conducted to increase the number of events avail-
able for analysis. The incidences of three-component MACE and other
CV outcomes were analysed using a stratified Cox proportional haz-
ards model with treatment as a categorical fixed factor stratified by
trial (SUSTAIN 6 or PIONEER 6) and CV risk at screening (established
CVD and/or CKD, or CV risk factors only).
For the subgroup analyses, the subgroup was added as a categori-
cal fixed factor and interaction term. Consistency across the
TABLE 1 Baseline characteristics and
demographics of the combined SUSTAIN
6 and PIONEER 6 population
Semaglutide Placebo Total
n = 3239 n = 3241 N = 6480
Baseline characteristics, mean (SD) (except where n [%])
Age, years 65.3 (7.2) 65.5 (7.4) 65.4 (7.3)
Female, n (%) 1142 (35.3) 1160 (35.8) 2302 (35.5)
Diabetes duration, years 14.4 (8.4) 14.3 (8.3) 14.4 (8.3)
BMI, kg/m2 32.5 (6.4) 32.5 (6.3) 32.5 (6.4)
HbA1c, % 8.4 (1.5) 8.4 (1.6) 8.4 (1.6)
SBP, mmHg 135.7 (17.5) 135.5 (17.2) 135.6 (17.4)
DBP, mmHg 76.6 (10.1) 76.5 (10.0) 76.6 (10.0)
Total cholesterol, mmol/L (geometric mean [CoV]) 4.1 (26.9) 4.1 (26.5) 4.1 (26.7)
Current smoker, n (%) 388 (12.0) 367 (11.3) 755 (11.7)
CVD, n (%)
Prior MI 1090 (33.7) 1131 (34.9) 2221 (34.3)
Prior stroke or TIA 499 (15.4) 522 (16.1) 1021 (15.8)
Prior arterial revascularization 1427 (44.1) 1489 (45.9) 2916 (45.0)
≥50% stenosis on angiography 991 (30.6) 1050 (32.4) 2041 (31.5)
History of symptomatic coronary heart disease 606 (18.7) 611 (18.9) 1217 (18.8)
Asymptomatic cardiac ischaemia 172 (5.3) 163 (5.0) 335 (5.2)
HF (NYHA Class II–III) 473 (14.6) 488 (15.1) 961 (14.8)
CKD (eGFR <60 mL/min/1.73 m2) 849 (26.2) 844 (26.0) 1693 (26.1)
CV risk factors, n (%)
Microalbuminuria or proteinuria 309 (9.5) 314 (9.7) 623 (9.6)
Hypertension and left ventricular hypertrophy 204 (6.3) 185 (5.7) 389 (6.0)
Left ventricular systolic or diastolic dysfunction† 134 (4.1) 127 (3.9) 261 (4.0)
Ankle/brachial index <0.9 59 (1.8) 56 (1.7) 115 (1.8)
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CoV, coefficient of variation; CV,
cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular
filtration rate; HF, heart failure; MI, myocardial infarction; NYHA, New York Heart Association;
SBP, systolic blood pressure; SD, standard deviation; TIA, transient ischaemic attack.
†Dysfunction was determined from imaging by the investigators according to local procedures. Data
were combined for semaglutide and placebo treatment groups in SUSTAIN 6 and PIONEER 6.
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Time since randomization (weeks)
Week 0 16 32 48 64 80 96
S.c. semaglutide OW 1,648 1,619 1,601 1,584 1,568 1,543 1,524
Placebo 1,649 1,616 1,586 1,567 1,534 1,508 1,479
Week 0 9 18 27 36 45 54 63 72 83
Oral semaglutide OD 1,591 1,583 1,575 1,564 1,557 1,547 1,512 1,062 735 16
Placebo 1,592 1,577 1,565 1,551 1,538 1,528 1,489 1,032 713 11
Number of  subjects at risk
S.c. semaglutide OW 
(SUSTAIN 6)
Placebo
(SUSTAIN 6)
Placebo
(PIONEER 6)
Oral semaglutide OD
(PIONEER 6)
SUSTAIN 6
HR: 0.74 (95% CI 0.58, 0.95)
P<0.001 for noninferiority
P=0.02 for superiority†
PIONEER 6
HR: 0.79 (95% CI 0.57;1.11)
P<0.001 for noninferiority
P=0.17 for superiority
F IGURE 1 Cumulative incidence plot of time to first occurrence of event adjudication committee-confirmed three-component major adverse
cardiovascular events (MACE) (cardiovascular [CV] death, nonfatal myocardial infarction [MI] and nonfatal stroke) with semaglutide versus
placebo in SUSTAIN 6 and PIONEER 6. Combined population omitted owing to different trial durations; SUSTAIN 6 and PIONEER 6 have already
been individually reported.32,33 Data are “in-trial”, analysed using Cox proportional hazards models with treatment as categorical fixed factor,
stratified by CV risk at screening (established cardiovascular disease [CVD] and/or chronic kidney disease [CKD], or CV risk factors only). †Not
prespecified. CI, confidence interval; HR, hazard ratio; OD, once daily; OW, once weekly; s.c., subcutaneous
No. of events/analysed subjects 
[incidence rate per 100 subject-years]
HR (95% CI)Semaglutide Placebo
MACE
SUSTAIN 6 108/1,648 [3.2] 146/1,649 [4.4] 0.74 (0.58, 0.95)
PIONEER 6 61/1,591 [2.9] 76/1,592 [3.7] 0.79 (0.57, 1.11)
SUSTAIN 6 + PIONEER 6 169/3,239 [3.1] 222/3,241 [4.2] 0.76 (0.62, 0.92)
CV death
SUSTAIN 6 44/1,648 [1.3] 46/1,649 [1.4] 0.98 (0.65, 1.48)
PIONEER 6 15/1,591 [0.7] 30/1,592 [1.4] 0.49 (0.27, 0.92)
SUSTAIN 6 + PIONEER 6 59/3,239 [1.1] 76/3,241 [1.4] 0.78 (0.56, 1.10)
Nonfatal MI
SUSTAIN 6 47/1,648 [1.4] 64/1,649 [1.9] 0.74 (0.51, 1.08)
PIONEER 6 37/1,591 [1.8] 31/1,592 [1.5] 1.18 (0.73, 1.90)
SUSTAIN 6 + PIONEER 6 84/3,239 [1.5] 95/3,241 [1.8] 0.88 (0.66, 1.18)
Nonfatal stroke
SUSTAIN 6 27/1,648 [0.8] 44/1,649 [1.3] 0.61 (0.38, 0.99)
PIONEER 6 12/1,591 [0.6] 16/1,592 [0.8] 0.74 (0.35, 1.57)
SUSTAIN 6 + PIONEER 6 39/3,239 [0.7] 60/3,241 [1.1] 0.65 (0.43, 0.97)
0.1 1.0 10.0
HR (semaglutide:placebo)
Favours semaglutide Favours placebo
Time to first event
F IGURE 2 Time to first occurrence of event adjudication committee-confirmed three-component major adverse cardiovascular events
(MACE) (cardiovascular [CV] death, nonfatal myocardial infarction [MI] and nonfatal stroke) and its components with semaglutide versus placebo
in SUSTAIN 6 and PIONEER 6. SUSTAIN 6 and PIONEER 6 have already been individually reported.32,33 Data are “in-trial”, analysed using Cox
proportional hazards models with treatment as a categorical fixed factor, stratified by trial (SUSTAIN 6 or PIONEER 6) and CV risk at screening
(established cardiovascular disease [CVD] and/or chronic kidney disease [CKD], or CV risk factors only). CI, confidence interval; CV, cardiovascular;
HR, hazard ratio; MACE, major adverse cardiovascular events; MI, myocardial infarction
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subgroups of the treatment effect on time to first occurrence of
MACE was assessed using interaction P-values.
For the post hoc analyses of data from the SUSTAIN and
PIONEER glycaemic efficacy trials combined, times from randomiza-
tion to first event adjudication committee-confirmed MACE were
analysed using a Cox proportional hazards model with treatment as a
categorical fixed factor and stratified by trial.
All analyses were performed using data from randomization to
follow-up (“in-trial” observation period).
3 | RESULTS
3.1 | Subject disposition and baseline
characteristics
SUSTAIN 6 and PIONEER 6 included 6480 subjects, of whom 3239
were randomized to semaglutide (s.c. or oral) and 3241 to placebo.
Key baseline characteristics are provided for this combined popula-
tion overall and by treatment group (Table 1), and for each subgroup
(Table S4). Individual trial data for each subgroup are shown in Tables S5
and S6. The treatment groups in SUSTAIN 6 and PIONEER 6 trials, indi-
vidually and as a combined population, were well balanced in terms of
baseline characteristics, CVD, and CV risk factors.32,33
Key baseline characteristics of subjects in the SUSTAIN and PIO-
NEER glycaemic efficacy trials and their combined population are pro-
vided in Table S7. These trials included subjects from across the
continuum of T2D care who were at a lower risk of CV events com-
pared with subjects enrolled in the CVOTs.
3.2 | Time to first occurrence of CV outcomes in
the CVOTs
Cumulative incidence plots of time to first occurrence of MACE in
SUSTAIN 6 and PIONEER 6 have been reported for each trial
individually,32,33 and are shown in Figure 1 (data from the combined
population are not presented owing to differences in trial durations).
In SUSTAIN 6 and PIONEER 6 combined, the incidence rates of
MACE were 3.1 and 4.2 events per 100 subject-years with
No. of events/analysed subjects 
[incidence rate per 100 subject-years]
HR (95% CI)
Interaction 
P-valueSemaglutide Placebo
SUSTAIN 6
Total population 108/1,648 [3.2] 146/1,649 [4.4] 0.74 (0.58, 0.95)
Evidence of CVD
Established CVD and/or CKD 98/1,353 [3.6] 137/1,382 [5.0] 0.72 (0.55, 0.93)
0.493
CV risk factors only 10/295 [1.6] 9/267 [1.6] 1.00 (0.41, 2.46)
Prior MI or stroke
Yes 66/673 [5.0] 88/694 [6.5] 0.76 (0.55, 1.05)
0.754
No 42/975 [2.1] 58/955 [3.0] 0.70 (0.47, 1.04)
Prior HF 
(NYHA Class II or III)
Yes 35/285 [6.2] 34/288 [6.0] 1.03 (0.64, 1.66)
0.091
No 73/1,363 [2.6] 112/1,361 [4.1] 0.64 (0.48, 0.86)
PIONEER 6
Total population 61/1,591 [2.9] 76/1,592 [3.7] 0.79 (0.57, 1.11)
Evidence of CVD
Established CVD and/or CKD 57/1,350 [3.2] 68/1,345 [3.9] 0.83 (0.58, 1.17)
0.443
CV risk factors only 4/241 [1.3] 8/247 [2.5] 0.51 (0.15, 1.68)
By prior MI or stroke
Yes 41/693 [4.6] 44/735 [4.7] 0.97 (0.64, 1.49)
0.163
No 20/884 [1.7] 32/845 [2.9] 0.59 (0.34, 1.03)
Prior HF 
(NYHA Class II or III)
Yes 16/188 [6.8] 15/200 [6.0] 1.14 (0.56, 2.31)
0.237
No 43/1,384 [2.4] 60/1,378 [3.4] 0.70 (0.47, 1.04)
SUSTAIN 6 + 
PIONEER 6
Total population 169/3,239 [3.1] 222/3,241 [4.2] 0.76 (0.62, 0.92)
Evidence of CVD
Established CVD and/or CKD 155/2,703 [3.5] 205/2,727 [4.6] 0.75 (0.61, 0.93)
0.944
CV risk factors only 14/536 [1.5] 17/514 [2.0] 0.77 (0.38, 1.57)
By prior MI or stroke
Yes 107/1,366 [4.8] 132/1,429 [5.8] 0.83 (0.64, 1.07)
0.292
No 62/1,859 [2.0] 90/1,800 [3.0] 0.67 (0.48, 0.92)
Prior HF 
(NYHA Class II or III)
Yes 51/473 [6.4] 49/488 [6.0] 1.06 (0.72, 1.57)
0.046
No 116/2,747 [2.5] 172/2,739 [3.8] 0.67 (0.53, 0.84)
0.1 1.0 10.0
Time to first event
HR (semaglutide:placebo)
Favours semaglutide Favours placebo
F IGURE 3 Time to first occurrence of event adjudication committee-confirmed three-component major adverse cardiovascular events
(MACE) (cardiovascular [CV] death, nonfatal myocardial infarction [MI] and nonfatal stroke) with semaglutide versus placebo in SUSTAIN 6 and
PIONEER 6 CV risk subgroups. SUSTAIN 6 and PIONEER 6 have already been individually reported.32,33 Data are “in-trial”, analysed using Cox
proportional hazards models with treatment and subgroup as categorical fixed factors, with interaction term between treatment and subgroup,
stratified by trial and CV risk at screening. P-value: unadjusted interaction test between treatment and subgroups. CI, confidence interval;
CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio; MI, myocardial infarction;
NYHA, New York Heart Association
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semaglutide and placebo, respectively (HR 0.76 [95% CI 0.62, 0.92];
Figure 2). The HRs for each individual component of MACE were
<1.0, although the upper limit of the 95% CI was <1.0 for nonfatal
stroke only (Figure 2).
When fatal and nonfatal MI events were analysed together in
SUSTAIN 6 and PIONEER 6 combined, the incidence rates were 1.7
and 1.9 events per 100 subject-years with semaglutide and placebo,
respectively (HR 0.89 [95% CI 0.67, 1.18]; Figure S1). For fatal and
nonfatal stroke events, these were 0.8 and 1.2 events per 100 sub-
ject-years (HR 0.68 [95% CI 0.46, 1.00]; Figure S1).
The incidence rates for hospitalization for HF in the combined
population from the CVOTs with semaglutide and placebo, respec-
tively, were 1.5 and 1.4 events per 100 subject-years (HR 1.03 [95%
CI 0.75, 1.40]; Figure S1).
3.3 | Time to first occurrence of MACE in
subgroups of CV risk in the CVOTs
The incidence rates and HRs (95% CIs) for the effects of semaglutide
versus placebo on MACE in each CV risk subgroup in SUSTAIN 6 and
PIONEER 6 individually and combined are shown in Figure 3.
In the combined population, the HRs for MACE were <1.0 in each
CV risk subgroup, with the exception of those with prior HF (HR 1.06
[95% CI 0.72, 1.57]; Figure 3). The 95% CIs spanned 1.0 for the following
subgroups: CV risk factors only, prior MI or stroke, and prior HF (Figure 3).
P-values for the interaction of the presence of CVD and/or CKD at
baseline, and prior MI or stroke on MACE were not significant (P > 0.05),
suggesting no heterogeneity in the treatment effects across these sub-
groups. The P-value for the interaction of prior HF was nominally signifi-
cant (P = 0.046); however, this was not controlled for multiple
comparisons.
3.4 | Time to first occurrence of MACE in the
phase 3a glycaemic efficacy trials
In the combined SUSTAIN and PIONEER glycaemic efficacy trials, the
incidence rates for MACE were 0.7 and 0.9 events per 100 subject-
years with semaglutide and comparator, respectively (HR 0.85 [95%
CI 0.55, 1.33]; Figure 4). A sensitivity analysis was performed, in
which all subjects who were receiving an SGLT-2i or a GLP-1RA at
baseline or initiated such therapies during the trial were excluded. In
this analysis, the HR for MACE was 0.77 (95% CI 0.47, 1.27) with
semaglutide versus comparators.
4 | DISCUSSION
In the combined SUSTAIN 6 and PIONEER 6 population, semaglutide
reduced the risk of MACE versus placebo in subjects with T2D at high
risk of CV events. While the HRs for each component of MACE
favoured semaglutide versus placebo, the HR for overall MACE was
mainly driven by the effect of semaglutide on nonfatal stroke and the
HRs were not statistically significant for CV death or nonfatal
MI. When fatal and nonfatal MI, and fatal and nonfatal stroke events
were analysed in the combined CVOT population, there was no signif-
icant effect of semaglutide versus placebo, consistent with the effect
of semaglutide on the CV death component of the primary endpoint.
Furthermore, no significant effect of semaglutide versus placebo on
hospitalization for HF was observed in the combined analysis of the
CVOTs. The effect of semaglutide on overall MACE in the combined
population of SUSTAIN 6 and PIONEER 6 was consistent irrespective
of baseline CV risk, with the exception of subjects with prior HF.
The subgroup analysis by subjects’ history of CVD (established
CVD and/or CKD vs. CV risk factors only) was based on the inclusion
No. of events/analysed subjects 
[incidence rate per 100 subject-years]
HR (95% CI)Semaglutide Comparator
SUSTAIN glycaemic 
efficacy trials
13/3,150 [0.4] 8/1,657 [0.5] 0.85 (0.35, 2.06)
PIONEER glycaemic 
efficacy trials
42/4,119 [0.9] 26/2,239 [1.1] 0.84 (0.50, 1.40)
SUSTAIN and PIONEER 
glycaemic efficacy trials
55/7,269 [0.7] 34/3,896 [0.9] 0.85 (0.55, 1.33)
Time to first event
HR (semaglutide:comparator)
Favours semaglutide Favours comparator
0.1 1 10
F IGURE 4 Time to first occurrence of major adverse cardiovascular events (MACE) (cardiovascular [CV] death, nonfatal myocardial infarction
[MI] and nonfatal stroke) across the SUSTAIN and PIONEER phase 3a glycaemic efficacy trials. Data are “in-trial” from SUSTAIN 1–5 and two
SUSTAIN JAPAN trials, and PIONEER 1–5, 7–8 and the two PIONEER Japanese trials (9 and 10). Times from randomization to first event
adjudication committee-confirmed MACE analysed using a stratified Cox proportional hazards model with treatment as a categorical fixed factor
and stratified by trial. See Tables S2 and S3 for details of comparators. CI, confidence interval; HR, hazard ratio
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criteria of the CVOTs, which can differ across trials. Although these
inclusion strata are suitable for identifying subjects at high risk of
MACE, they are not ideal for clinical decision-making. In practice, deci-
sions are typically based on the presence or absence of a prior CV
event, making subgroup analyses based on prior MI or stroke, or his-
tory of HF, more relevant. It should be noted that the subgroup ana-
lyses were not mutually exclusive.
Findings from the SUSTAIN and PIONEER glycaemic efficacy tri-
als also suggest a potentially beneficial effect of semaglutide on
MACE in subjects with T2D at low risk of MACE. These data were
included to investigate the effects of semaglutide in a population of
patients with T2D considered to be at a lower CV risk than those in
the CVOTs. However, the number of events was small; accordingly,
the 95% CIs were broad and not statistically significant. Furthermore,
the pooling of placebo and active comparators (including liraglutide
and empagliflozin, for which CV benefits have been demonstrated)2,5
may confound the ability of this analysis to detect a benefit of
semaglutide. Results were similar, however, when subjects receiving a
GLP-1RA or an SGLT-2i were excluded from the analysis.
Once absorbed, s.c. and oral semaglutide share similar pharmacoki-
netic profiles and effects.14,15 It has been shown that median exposure
of s.c. semaglutide 1.0 mg is higher than oral semaglutide 14 mg. How-
ever, the exposure range following orally administered semaglutide is
wider than for s.c. semaglutide, with a considerable overlap between oral
semaglutide 14 mg and s.c. semaglutide 1.0 mg. This indicates similar
exposure levels across the two formulations. Furthermore, similar expo-
sure−response relationships were observed for the efficacy (HbA1c and
body weight reduction) and tolerability of semaglutide, regardless of the
route of administration.34 The HRs for MACE in SUSTAIN 6 and
PIONEER 6 were similar,32,33 despite the different administration routes.
These factors support a similar potential of oral and s.c. semaglutide in
conferring clinical benefits and mediating CV effects at the doses used in
the CVOTs, implying that either could be used in clinical practice. Addi-
tionally, the similarity in trial designs, study populations and outcomes in
SUSTAIN 6 and PIONEER 6 adds to the comparability of the trials, and
supports the scientific validity of a combined analysis.
Although comparison across CVOTs is not straightforward, owing
to subjects in each trial having different risk profiles, our combined
SUSTAIN 6 and PIONEER 6 findings are consistent with other trials.
The superiority of a GLP-1RA versus placebo has been demonstrated
in LEADER,2 HARMONY3 and REWIND,4 and noninferiority demon-
strated in EXSCEL35 and ELIXA.36 Subjects’ CV risk in these trials var-
ied from all having established CVD (HARMONY) to only one third
having established CVD (REWIND). There are, however, conflicting
data for the effects of GLP-1RAs on MACE in a population at high CV
risk. In ELIXA, the HR for the effect of lixisenatide versus placebo on
MACE was 1.02 but nonsignificant in a population who had experi-
enced a recent acute coronary event,36 arguably one of the highest
risk patient populations encountered in clinical practice.
A prespecified analysis of REWIND showed similar estimated
effects of dulaglutide on MACE in subjects with and without
established CVD4; however, it should be noted that the definition of
“established CVD” can differ across CVOTs. In analyses of GLP-1RA
CVOTs in which MACE in subjects with and without prior HF were
assessed (LEADER, EXSCEL and HARMONY), the HRs were always
<1.0 irrespective of subgroup, and the tests for interaction nonsignifi-
cant (P > 0.05), suggesting consistent effects irrespective of subjects’
CV risk at baseline.2-4,35
Post hoc analyses of CVOTs also support the CV effects of GLP-
1RAs in subjects with T2D across the spectrum of CV risk. MACE in
LEADER have been assessed in three different subgroup analyses: by
prior MI or stroke status37; by baseline vascular disease38; and by
prior HF (NYHA Class I–III, yes/no).39 The HRs favoured liraglutide
versus placebo in all subgroups, apart from the subgroups at lowest
CV risk in the former two analyses.37-39 The interaction of CV risk sta-
tus at baseline on the treatment effect of liraglutide was not signifi-
cant in any analysis, suggesting consistent CV effects across clinically
relevant subgroups.37,38 These findings may seem inconsistent with a
prespecified subgroup analysis of LEADER, in which a significant
interaction of treatment effect on MACE was observed in those aged
≥50 years with established CVD or CKD versus those aged ≥60 years
with risk factors for CVD.2 However, considering the broad 95% CI in
the CV risk factor only subgroup (0.86, 1.67), further study is
warranted. In a post hoc analysis of subjects with and without prior
MI or stroke in REWIND, the HR for MACE was <1.0 in each sub-
group and the interaction nonsignificant, supporting a consistent ben-
efit of dulaglutide.4 Although the effect of exenatide extended release
on MACE was not superior to placebo in the full population of
EXSCEL, a post hoc analysis of subjects with prior CVD showed an
HR of 0.90 (95% CI 0.816, 0.999) for the effect on MACE versus
placebo.40
A recent meta-analysis of GLP-1RAs suggests that their CV bene-
fits should be regarded as a class effect, and that timing of exposure is
the most prominent factor in trial heterogeneity, with increased expo-
sure associated with improved outcomes.41 The benefits of GLP-1RAs
on CV outcomes in subjects with T2D have also recently been con-
firmed in an analysis of the seven GLP-1RA CVOTs described above,
and are consistent irrespective of CVD at baseline.42
In our analyses, a significant interaction of prior HF status on
the effect of semaglutide versus placebo on MACE was detected.
However, the numbers of events were low (51 and 49 [with prior
HF], and 116 and 172 [without prior HF], with semaglutide and pla-
cebo, respectively), resulting in a broad 95% CI and a nominally sig-
nificant P-value uncontrolled for multiplicity. The proportion of
subjects with prior HF in this analysis (~15%) is similar to the pro-
portions in the prespecified subgroup analyses of LEADER2 and
EXSCEL,35 in which the CIs also spanned 1.0. In the post hoc analy-
sis of MACE by prior HF in LEADER, there were 142 and 170 (with
prior HF), and 466 and 524 (without prior HF) events with
liraglutide and placebo, respectively.39 The interaction P-value
suggested no effect of prior HF status on the treatment effect on
MACE (P = 0.528).39
When considering HF as an endpoint in its own right, no effect of
liraglutide, semaglutide (s.c. or oral), exenatide extended release or
dulaglutide was observed compared with placebo in their respective
CVOTs.2,4,32,33,35 However, a benefit was observed with albiglutide in
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HARMONY3 and, furthermore, a recent meta-analysis that included
data from seven CVOTs showed that treatment with a GLP-1RA
results in a small but significant reduction in the risk of hospitalization
for HF versus placebo.42 Conversely, in two small studies of liraglutide
in subjects with HF with reduced ejection fraction (with or without
T2D), there was no difference in the incidence of death or
rehospitalization for HF, but a higher incidence of cardiac serious AEs
compared with placebo, although the types of events were heteroge-
neous (ventricular tachycardia, atrial fibrillation, acute
coronary syndrome and worsening of chronic HF) and the overall inci-
dence was low.43,44 It has been suggested that the benefits of GLP-
1RAs on HF are secondary to the reduced risk of MI, which would
account for the results in the HARMONY trial, in which the risk
reduction for hospitalization for HF and MI was greater than in
other GLP-1RA CVOTs.42 Consistent with this, in our analysis of
SUSTAIN 6 and PIONEER 6 combined, semaglutide had neutral
effects on both MI and hospitalization for HF compared with pla-
cebo. Taken together, these data suggest that GLP-1RAs have a
consistent effect on MACE in subjects with T2D and CVD, there
are no overall safety concerns regarding their effects on HF, and
they should be considered in those with T2D and HF, as suggested
in recent guideline updates.11
Reporting safety data is beyond the scope of the current analysis;
however, the safety profile of semaglutide in each SUSTAIN and
PIONEER trial individually has previously been reported.16-33
The limitations of our analysis include the low number of CV
events and the short trial durations of SUSTAIN 6 (planned exposure
104 weeks and median follow-up 2.1 years) and PIONEER 6 (median
follow-up 1.3 years) compared with other CVOTs. This resulted in
small sample sizes and event numbers. Although findings from the
SUSTAIN and PIONEER glycaemic efficacy trials support those of the
CVOTs, the small number of events mean they should be interpreted
with caution. Indeed, interpretation of subgroup analyses also
requires caution, as our analyses (as with others discussed here) have
not been controlled for multiplicity. There are additional limitations
inherent to post hoc (versus prospective) analyses of randomized clini-
cal trials.
Limitations aside, the data reported here add to the growing body
of evidence on the CV benefits of GLP-1RAs, specifically semaglutide,
in patients with T2D across the spectrum of CV risk. It will be impor-
tant to analyse the results of other randomized clinical trials in sub-
jects with T2D by key demographics and baseline disease measures to
confirm these findings and further inform optimal T2D care and CV
risk management.
In conclusion, this post hoc analysis of a combined population
from the SUSTAIN 6 and PIONEER 6 CVOTs showed that
semaglutide reduced the risk of MACE versus placebo in subjects with
T2D by 24%. This effect appeared to be consistent across the s.c. and
oral formulations of semaglutide, and across several clinically relevant
subgroups, namely those with and without established CVD and/or
CKD, and with and without prior MI or stroke. In subjects with prior
HF (NYHA Class II–III), no effect of semaglutide versus placebo on
MACE was observed, although the overall incidence in the subgroup
with prior HF was low. These findings are further supported by an
analysis of combined data from the SUSTAIN and PIONEER glycaemic
efficacy trials, which compared semaglutide with placebo and active
comparators in subjects with T2D at a relatively low risk of CV events.
Collectively, these analyses suggest a CV benefit of semaglutide not
only in those with a history of CVD, but also in lower CV risk sub-
groups, and that the effect was similar despite different routes of
treatment administration.
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